The efforts, though, will take years for ZimVie (NASDAQ:ZIMV), the new Zimmer Biomet (NYSE:ZBH) spinoff of its spine and dental businesses.
That was the big takeaway when MassDevice and Medical Design & Outsourcing caught up with Jamali today, shortly after he rang in the Nasdaq on the first day of trading for ZIMV shares. (Listen to the full interview during our upcoming DeviceTalks Weekly podcast.)
Over the past decade, Jamali rose through the ranks at Covidien and then Medtronic after the $50 billion merger of the two companies in 2015. His focus over the years was growing business in the gastroenterological diseases space.
Now Jamali has the chance to do it again in the spine and dental area — except he can run it all from the corner office.
“The responsibility is yours and the decision-making is yours,” Jamali said. “It’s very different than how it is inside of a large company, where you have a lot of responsibility, but ultimately there’s somebody watching over and making the last call in many cases.”
The 2,700-employee company has its headquarters in Westminster, Colorado. It’s competing in the spine device space where Jamali’s former colleagues at Medtronic have created plenty of excitement with their Mazor surgical robots. ZimVie could have opportunities to fill some gaps in complex spine surgery offerings, but Jamali sees other areas in the spine space that provide growth opportunities.
